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794Favorable Outcomes in Patients with High
Donor-Derived T Cell Count after In Vivo
T Cell–Depleted Reduced-Intensity Allogeneic Stem
Cell Transplantation
Amir A. Toor,1 Roy T. Sabo,2 Harold M. Chung,1 Catherine Roberts,1
Rose H. Manjili,1 Shiyu Song,3 David C. Williams, Jr.,4 Wendy Edmiston,1
Mandy L. Gatesman,1 Richard W. Edwards,1 Andrea Ferreira-Gonzalez,4
William B. Clark,1 Michael C. Neale,5,6 John M. McCarty,1 Masoud H. Manjili7Patients with hematologic malignancies were conditioned using a rabbit antithymocyte globulin–based
reduced-intensity conditioning regimen for allogeneic stem cell transplantation. Donor-derived CD31 cell
count (ddCD3), a product of CD31 cell chimerism and absolute CD31 cell count, when\110/mL at 8 weeks
post-stem cell transplantation predicted a high risk of sustained mixed chimerism and relapse. Alternatively,
patients with a higher ddCD3 developed graft-versus-host disease more frequently, and when partially chi-
meric, had higher rates of conversion to full donor chimerism after withdrawal of immunosuppression. Early
data from our small cohort of patients indicate that ddCD3 at 8 weeks may be used to guide decisions
regarding withdrawal of immunosuppression and administration of donor lymphocyte infusion in partially
T cell–depleted reduced-intensity regimens.
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RelapseINTRODUCTION
Reduced-intensity conditioning regimens for
allogeneic stem cell transplantation (SCT) are well
tolerated but are characterized by variable immuno-
logic recovery, particularly when T cell depletion
(TCD) is performed to reduce graft-versus-host
disease (GVHD) risk [1-5]. TCD may be performed
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6/j.bbmt.2011.10.011globulin (ATG) during conditioning or ex vivo by
various allograft T cell–purging techniques. ATG
reduces the risk of chronic GVHD and nonrelapse
mortality in matched related donor (MRD) SCT
recipients conditioned with a myeloablative regimen
[6]. In addition, outcomes in unrelated donor (URD)
SCT are improved when ATG is incorporated in the
conditioning regimen [7,8] or when the allograft is
ex vivo T cell–depleted with CD6 monoclonal
antibodies [9].
However, when TCD is performed in SCT with
a reduced-intensity conditioning regimen, post-SCT
outcomes such as GVHD and relapse are influenced
by the level of donor T cell chimerism achieved. Mixed
donor–recipient chimerism inT cells often complicates
such transplantations. A recent study found that the use
ofCD52monoclonal antibody forTCDalongwitha re-
duced-intensity regimen resulted in a 50% incidence of
mixed chimerism (MC) in T cells at day 100 post-SCT
and that decliningT cell chimerismwas associated with
increased risk of relapse [10]. Other studies have re-
ported similarly poor outcomes with MC in the T cells
in the first month after reduced-intensity SCT,
particularly when T cell chimerism was \60% [11].
Biol Blood Marrow Transplant 18:794-804, 2012 795Donor-Derived CD3+ Cell Count in SCTThe level of T cell chimerism after SCT also affects
the response to donor lymphocyte infusion (DLI). In
one study, patients conditioned with ATG and
a reduced-intensity regimen before allografting had
a high rate of graft loss despite prophylactic DLI if
T cell chimerism was\20% donor and a high rate of
conversion to full donor chimerism (FC) if T cell chi-
merism was .40% donor [12]. In addition to T cells,
natural killer (NK) cell chimerism also has been
reported to affect the risk for GVHD and graft loss in
patients undergoing T cell–replete nonmyeloablative
allogeneic SCT [13], highlighting the interactions
among various effectors of cellular immunity. In
general, studies incorporating T cell–replete allografts
have reported frequent mixed donor–recipient chime-
rism inT cells early after reduced-intensity SCT,which
over time converts to FC as immunosuppression is
withdrawn. Often this shift in chimerism is acc-
ompanied by the development of GVHD, potentially
compromising outcome. Conversely, in patients
undergoing TCD allogeneic SCT, withdrawal of im-
munosuppression results in less precisely predictable
outcomes in patients with mixed T cell chimerism,
with either maintenance of stable MC or occasionally
graft loss observed. MC is accompanied by an
increased risk of relapse [14,15]. DLI may be used to
convert patients with MC to FC and reduce the risk of
relapse, but it is complicated by the development of
acute or chronic GVHD in as many as 50% of
patients [16,17], even when CD8-depleted DLI is
used [18,19]. Alternative strategies in patients with
MC, such as administration of low-dose prophylactic
DLI, although less likely to cause GVHD, are
ineffective [4].
Given the unfavorable outcomes associatedwith the
mixed chimeric state, a reliable predictor for the ex-
pected evolution of mixed T cell chimerism is needed
to help guide clinical decision making regarding
withdrawal of immunosuppression and DLI. An
alternative immune recovery parameter with prognostic
value is T cell recovery posttransplantation [20,21].We
decided to combine this measure with T cell chimerism
and to examine the predictive value of a calculated
donor-derived T cell count for clinical outcomes after
allogeneic SCT conditioned with rabbit ATG and
reduced-intensity total body irradiation (TBI). This
regimen is based on preclinical studies in murine trans-
plantation demonstrating engraftment across the major
histocompatibility complex barrier when T cell anti-
bodies were combined with low-dose irradiation
[22,23]. The feasibility of this approach in human
transplantation has been demonstrated in clinical
trials, which established a low risk of severe acute
GVHD, albeit with high rates of mixed donor–
recipient chimerism and occasional graft loss
[1,3,12,24]. The present trial examined the effect of
two doses of rabbit ATG in recipients of allogeneicSCT, with posttransplantation immune reconstitution
as the trial’s primary endpoint (Clinicaltrials.gov
identifier: NCT00709592).PATIENTS AND METHODS
Patients and Eligibility
Consecutive patients were enrolled on a prospec-
tive randomized phase II clinical trial, approved by
the Institutional Review Board at Virginia Common-
wealth University. To be eligible, patients had to be
between 18 and 70 years of age, have a recurrent or
high-risk hematologic malignancy, and have adequate
end-organ function and performance status. Patients
aged\50 years had to be ineligible for conventional
myeloablative conditioning because of comorbidity.
Each patient was required to have a 7/8 or 8/8 locus-
matched related donor (MRD) or unrelated donor
(URD), with high-resolution typing performed for
HLA-A, -B, -C, and -DRB1.
ATG 1 TBI Conditioning Regimens
The patients were randomized between two differ-
ent doses of rabbit ATG (Thymoglobulin; Genzyme,
Cambridge, MA), 2.5 or 1.7 mg/kg adjusted ideal
body weight/day, given i.v. on days -9 through -7, fol-
lowed by TBI to a total dose of 4.5 Gy, delivered in
three 1.5-Gy fractions, with two doses on day -1 and
the final dose on day 0. Methylprednisolone 2 mg/kg
was given as premedication for ATG. GVHD prophy-
laxis was tacrolimus given orally starting on day -2 with
tapering starting at approximately 12 weeks posttrans-
plantation. Mycophenolate mofetil was given orally at
a dose of 15 mg/kg twice daily from day 0 to day 28.
Granulocyte colony-stimulating factor (G-CSF) was
given at a dose of 5 mg/kg/day from day 4 until myeloid
engraftment occurred. Blood stem cells were collected
using G-CSF 10 mg/kg/day s.c. on days 1-5.
Escalating-dose DLI was permitted beyond 8 weeks
post-SCT for the management of declining or persis-
tent MC (initial dose, 1  106 CD31 cells/kg)
and for disease progression (initial dose, 5  106
CD31 cells/kg).
T Cell Engraftment Analysis
Donor engraftment was assessed by chimerism
analyses performed at 4, 8, 12, and 24 weeks after
SCT on whole-blood, granulocytes, and total T cells.
Blood cell separation was done using immunomag-
netic beads (Miltenyi Biotec, Auburn, CA) enriched
for CD15- andCD3-expressing cells in aMiltenyi Bio-
tech AutoMACS Pro Separator. DNA was isolated us-
ing a Qiagen EZ1 200-mL Whole-blood Isolation Kit
(Qiagen, Valencia, CA) on a Qiagen EZ1 Biorobot.
Polymerase chain reaction was performed with the
796 Biol Blood Marrow Transplant 18:794-804, 2012A. A. Toor et al.GeneAmp PCR System 9700 (Applied Biosystems,
Carlsbad, CA) with the GenomeLab Human STR
Primer Set (Beckman Coulter, Brea, CA), and capillary
electrophoresis of the amplification products was per-
formed on a Beckman Coulter Vidiera NsD Analyzer
to determine the short tandem repeat (STR) alleles
of the donor and patient. Donor chimerism was calcu-
lated for each STR from the areas of unique recipient
and donor peaks using themanufacturer’s software and
averaged over all informative STR alleles. Immuno-
phenotypic analysis of the blood for immune reconsti-
tution was performed concomitantly with chimerism
analysis, using a dual-platform technique on a Beck-
man Coulter Cytomics FC500 flow cytometer. Anti-
bodies to CD3 and CD56 (Beckman Coulter) were
used to enumerate T cells and NK cells.
Donor-derived CD31 T cell count (ddCD3)
was calculated by multiplying the T cell chimerism
(% recipient DNA, expressed as a fraction) with the
absolute blood CD31 T cell count obtained simulta-
neously. The resulting absolute recipient-derived
CD31 T cell count was then subtracted from the
total absolute CD31 cell count to obtain the ddCD3
value.Study Design and Statistical Analysis
This randomized phase II study compared two dif-
ferent ATG doses used in conditioning and was de-
signed with immune reconstitution as the primary
endpoint, with engraftment, GVHD rate, and survival
as secondary endpoints. Engraftment was defined as
sustained hematopoietic recovery after SCT with
\5% recipient chimerism in whole blood or a relevant
cell fraction. Overall survival was calculated from the
day after transplantation to the day of death. GVHD
was classified according to consensus criteria. Acute
GVHDwas graded according to the Glucksberg crite-
ria. Because of the small patient number and relatively
low event rate, acute and chronic GVHD data were
pooled to analyze GVHD risk. GVHD observations
were censored if this complication developed after de-
livery of DLI. Disease-specific criteria were used to di-
agnose relapse or progression.
To determine the optimal cutoff for classifying our
patients into high ddCD3 and low ddCD3 groups, we
first measured the association between ddCD3 and
clinical outcomes of interest to determine the logistic
regression for each outcome, and then determined
the area under the curve (AUC) of the receiver-
operating characteristic (ROC) curve for logistic re-
gression for each clinical outcome of interest against
the ddCD3 value. The cutoff that maximized the
sum of ROC-AUC across all measures was selected.
The Kruskal-Wallis test was used to test for mean
differences in continuous variables between the high
ddCD3 and low ddCD3 groups. To further analyzethese relationships, an informative normal prior was
used for the mean measure in each ddCD3 group
(based on the overall sample mean and variance) and
was combined with a normal likelihood for the
observed data. Fisher’s exact test (FET) was used to
analyze the relationships between ddCD3 groups and
categorical measurements. As an additional analysis,
noninformative beta priors were assumed on the
proportions in both ddCD3 groups and were coupled
with binomial likelihoods for the observed data.
Kaplan-Meier curves were estimated to account for
the timing of remission and overall survival, and differ-
ences between the high ddCD3 and low ddCD3
groups were tested using the log-rank test. Corrobora-
tory Bayesmethods were used as well. For both contin-
uous and categorical cases, direct sampling (with
100,000 repetitions) from the conjugate posterior dis-
tributions for each ddCD3 group was used to estimate
posterior probabilities (PPs) of differences between the
two ddCD3 means or proportions [25]. For all fre-
quentist analyses, a mean or rate difference between
ddCD3 groups is considered significant for a P value
\.05, whereas for all Bayes analyses, a PP . 0.95 is
considered sufficient evidence of a mean or propor-
tional difference between the ddCD3 groups’ data
summaries. The Fisher’s exact test and the Kruskal-
Wallis test were applied using the FREQ andNPAR1-
WAY procedures in SAS 9.2 (SAS Institute, Cary,
NC), and Bayes analyses were conducted using R sta-
tistical software.RESULTS
Patients
Between 2008 and 2011, a total of 25 patients
were enrolled in this trial, 22 of whom were eligible
for the present analysis. One patient was excluded
because of disease progression and autologous recon-
stitution at 4 weeks after SCT, and two patients had
not been enrolled sufficiently long to be evaluated
for transplantation outcomes. The median age of the
22 evaluable patients was 58 years (range, 44-68 years).
The diagnoses were multiple myeloma in seven pa-
tients, non-Hodgkin’s lymphoma in six, chronic lym-
phocytic leukemia (or prolymphocytic leukemia) in
seven, and myelodysplastic syndrome and acute mye-
logenous leukemia in one each. Most of the patients
had experienced multiple relapses and had been
heavily pretreated, having received a median of four
previous rounds of chemotherapy (range, 2-10).
Eleven patients had undergone previous autologous
SCT. Fourteen patients were in complete remission
at the time of SCT, whereas eight patients were in par-
tial remission or had persistent, stable disease. Eleven
patients (50%) were included in each ATG dose co-
hort. The conditioning regimen was well tolerated,
Table 1. Patient Outcomes According to ddCD3 Cell Count at 8 Weeks Posttransplantation
Patient Donor
ATG Dose,
mg/kg
CD3 Cell Count,
Cells/mL
T Cell Chimerism; % Recipient
DNA in T Cells
ddCD3 Cell Count,
Cells/mL
GVHD
(Grade)
Disease
Status
Blood Engraftment
Weeks 12-54 DLI
16 MRD 5.1 5 4.7 3 No Relapse MC
5 URD 5.1 5 1 5 Acute (II)>prog CR FC
18 URD 5.1 39 23 30 No Relapse/PD MC Yes
7 URD 7.5 60 NE 60b No CR MC
23 MRD 7.5 90 26 67 No CR FC
20 MRD 7.5 85 11 76 No Relapse MC Yes
17 URDa 7.5 84 1 76 No Relapse/PD MC Yes
2 MRDa 7.5 2,646 96 106 No Relapse MC Yes
6 MRD 7.5 128 0 128 DOA (III)c CR FC
8 URD 7.5 336 0 336 OS CR FC
24 URD 5.1 413 0 413 Acute (II) CR FC
4 MRD 5.1 1,054 57 453 No CR FC
14 URDa 5.1 736 0 736 DOA (IV) CR FC
11 MRDa 7.5 770 0 770 Chronic CR FC
13 URD 5.1 828 0 828 Acute (II)>prog CR FC
12 URD 5.1 882 0 882 No CR FC
15 URD 7.5 957 0 957 Chronic CR FC
10 URD 7.5 1,170 0 1,170 Chronic Relapse FC Yes
19 MRD 5.1 1,530 4.7 1,458 DOA (III) CR FC
9 URD 7.5 1,550 0.7 1,539 Chronic CR FC
3 URD 5.1 2,050 6 1,923 No CR FC
21 MRD 5.1 2,464 0 2,464 No Relapse FC
CR indicates complete response; PD, persistent disease; NE, not evaluable; prog, progression to persistent grade III acute GVHD; DOA, delayed-onset
acute GVHD; OS, overlap syndrome.
aSingle-locus HLA class I mismatch (7/8 matched donor); blood chimerism: last value <5% recipient FC, >5% MC.
bThere was inadequate sample size for T cell chimerism determination at 8 weeks; thus, total CD3+ cell count was assumed to equal ddCD3 cell count;
MC at 12 weeks (51% recipient DNA).
cProgressed to extensive chronic GVHD.
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observed.
Engraftment and Chimerism
Predominantly donor-derived hematopoiesis
was established promptly after SCT. The median
whole-blood hematopoietic and granulocyte chime-
rism was 0% recipient-derived at all time points
evaluated after transplantation in the 22 evaluable
patients. Median T cell chimerism measured simulta-
neously was 5% at 4 weeks posttransplantation, 1.5%
at 8 weeks, 5% at 12 weeks, and 0% at 24 weeks.
T cell chimerism could not be evaluated in seven of
the 22 patients at 4 weeks posttransplantation because
of inadequate DNA yield related to lowT cell recovery
at that time. Nine of the 22 patients had mixed T cell
chimerism ($5% recipient DNA) at 8 weeks post-
transplantation, and three of these nine (33%) devel-
oped FC after withdrawal of immunosuppression
over the ensuing weeks. One of the nine patients dem-
onstrated improved donor chimerism after DLI, and
one of the 13 patients with FC reverted to MC.
Clinical Outcomes with ATG 1 TBI
Conditioning
Classical-onset acute cutaneous GVHD developed
in three patients (grade I-II in all), two of whom
evolved to progressive delayed-onset acute grade III-
IV gastrointestinal GVHD. Two other patients devel-oped delayed-onset acute gastrointestinal GVHD
(grade III-IV) after withdrawal of immunosuppression
(Table 1). Chronic GVHD has developed in five other
patients (four with classical onset and one with overlap
syndrome). All patients who developed GVHD
demonstrated FC at the time of GVHD diagnosis.
Relapse or persistent disease was observed in seven of
22 patients (32%), five of whom had MC or declining
T cell chimerism after initial engraftment. Five
patients received DLI at a median of 204 days after
SCT (range, 99-362 days) for the management of
persistent or relapsing diseasewithMC (n5 4) orwith-
out MC (n 5 1). Two of these patients died from
progressive disease (one patient despite developing
GVHD), whereas the other three remained progres-
sion free.
Donor-Derived CD31 Cell Count
T cell chimerism and simultaneously measured ab-
solute CD31 cell counts were used to calculate ddCD3
at 8 weeks after SCT, because reliable data were avail-
able for all patients for this interval. The median
ddCD3 value at 8 weeks was 433/mL (range, 3-2,464/
mL). After calculating the sum of ROC-AUCs for
each of the potential ddCD3 cutoff values (Figure 1),
a ddCD3 of 110/mL was found to be optimal, with
both the highest AUC sum and the highest AUC for
each measure (cumulative GVHD present or absent,
0.79; remission present or absent, 0.74; whole blood
chimerism, FC vs MC, 0.88). Thus, we used 110/mL
Figure 1. AUC for ROC curves for GVHD status, remission status, and whole blood chimerism against the ddCD3 group. The table lists ddCD3 cutoff
values calculated from the sum of AUCs for different ROC curves.
Table 3. Summary of Continuous (Sample Size [n], Median,
and Interquartile Range [IQR]) and Categorical (Sample
Size [n], Frequency, and Proportion) Measurements
Measurement
ddCD3 <110 ddCD3 >110
(n) Median IQR (n) Median IQR
Donor age 8 52 41-61 14 45 32-63
CD34+ cell dose 8 5.4 3.3-6.4 14 5.7 3.9-6.8
CD3+ cell dose 8 2.83 1.85-5.12 14 2.94 1.66-3.54
NK cell count at 8 183 53-201 14 185 144-264
798 Biol Blood Marrow Transplant 18:794-804, 2012A. A. Toor et al.as the cutoff value to distinguish between low (\110)
and high (.110) ddCD3 values. Based on this crite-
rion, there were eight patients in the low ddCD3 group
and 14 patients in the high ddCD3 group. Notably,
based on the cutoff of 110/ mL, the median ddCD3
in the corresponding groups was 60/mL in the low
ddCD3 group and 855/mL in the high ddCD3 group,
suggesting a marked difference in T cell reconstitution
between the two groups.
Clinical Impact of Donor-Derived CD31 Cell
Count
Significant relationships were found between
ddCD3 value and cumulative GVHD status (presentTable 2. Relative Clinical Outcomes in Patients with Low and
High ddCD3 Recovery
Measurement
ddCD3 <110 ddCD3 >110
(n) Frequency Proportion (n) Frequency Proportion
GVHD (yes) 7 1 0.14 14 10 0.71
Remission (yes) 8 3 0.38 14 12 0.86
Whole blood
chimerism (MC)
8 6 0.75 14 0 0.00or absent), remission status (present or absent), and
whole blood chimerism status (FC or MC), reflecting
engraftment at and beyond 12 weeks after SCT
(Table 2). Using frequentist methods, the proportion4 weeks
NK cell count at
8 weeks
8 129 49-210 14 221 85-300
ddCD3 8 63 18-76 14 855 453-1458
Measurement (n) Frequency Proportion (n) Frequency Proportion
Donor type
(MRD)
8 4 0.50 14 5 0.36
ATG dose
(5.1)
8 3 0.38 14 8 0.57
Figure 2. (A) Kaplan-Meier survival curve for overall survival time,
comparing the high ddCD3 (.110) and low ddCD3 (\110) groups.
(B) Kaplan-Meier survival curve for progression-free survival time, com-
paring the high ddCD3 and low ddCD3 groups. (C) Kaplan- Meier failure
curve for time to relapse, comparing the high ddCD3 and low ddCD3
groups.
Biol Blood Marrow Transplant 18:794-804, 2012 799Donor-Derived CD3+ Cell Count in SCTof patients with MC in whole blood was significantly
higher in the low ddCD3 group compared with the
high ddCD3 group (P\ .0001, FET). However, the
proportion of patients diagnosed with GVHD was
significantly lower in the low ddCD3 group
(P 5 .024, FET). The proportion of patients in
sustained remission was marginally lower in the low
ddCD3 group (P 5 .0524, FET). These results were
corroborated by Bayes analysis, which found higher
whole blood MC rates (PP 5 0.99), lower GVHD
rates (PP 5 0.99), and lower remission rates
(PP 5 0.99) in the low ddCD3 group. Consequently,
with a median follow-up of 18 months (range, 4-
29 months) in the surviving patients, both overall sur-
vival and progression-free survival (Figure 2A and B),
as well as time to relapse (Figure 2C), weremore favor-
able in the high ddCD3 group compared with the low
ddCD3 group. But although the relationship was
significant for relapse (c21 5 0.79; P 5 .005) and
progression-free survival (c2 5 5.3; P 5 .02), it was
only marginally significant for overall survival
(c21 5 3.2; P 5 .07). Correspondingly, 1-year
Kaplan-Meier estimates for overall survival (84% vs
54%) and progression-free survival (69% vs 15%)
were superior in the high ddCD3 group, with all
relapses occurring in the first year after SCT. Notably,
treatment-related mortality was similar in the two
groups (16% in the high ddCD3 group and 15% in
the low ddCD3 group).
To confirm the utility of ddCD3 value in predict-
ing clinical outcomes, we performed additional
analyses to assess the impact of its factors in isolation.
We found no significant associations between absolute
T cell count andT cell chimerism at 8 weeks after SCT
with mortality (T cell recovery, P 5 .65; % T cell
chimerism, P 5 .57), relapse (T cell recovery,
P 5 .51; % T cell chimerism, P 5 .47), or GVHD
(T cell recovery, P 5 .35; % T cell chimerism,
P 5 .21).
Kinetics of Donor-Derived T Cell Reconstitution
When examined over time, patients with a ddCD3
value \110/mL and MC had either declining donor
chimerism or persistent MC as immunosuppression
was withdrawn (Figure 3A), whereas those with
ddCD3 .110/mL had increasing donor T cell chime-
rism over time as immunosuppression was tapered
(Figure 3B). This resulted in a progressive rise in the
absolute ddCD3 value over time in the patients with
higher ddCD3 values (Figure 3C). Patients in the
high ddCD3 group demonstrated predominantly do-
nor chimerism in T cells at 6 months posttransplanta-
tion (Figure 3D). A modulating effect of ddCD3 value
on immunosuppression withdrawal was shown most
clearly in the rare patient with mixed granulocyte chi-
merism (Figure 4). Early DLI arrested the decline of
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recovery.Effect of Pretransplantation and
Posttransplantation Variables on ddCD3
No significant relationships were found between
ddCD3 level and donor age, donor type (MRD vs
URD), total ATG dose (5.1 mg/kg vs 7.5 mg/kg), orTime
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Figure 4. Effect of immunosuppression withdrawal on granulocyte chi-
merism in the high ddCD3 and low ddCD3 groups.infused CD341 or CD31 cell dose (Table 3). Using
frequentist methods, mean values for donor age (c21
5 0.5; P 5 .49), infused CD31 (c21 5 0; P 5 .84),
and CD341 cell dose (c21 5 0.5; P 5 .49), as well as
proportions for donor type (P 5 .66, FET) and ATG
dose (P 5 .66, FET), were not significantly different
between the low ddCD3 and high ddCD3 groups.
These results were corroborated by the Bayes statisti-
cal analysis, which showed low PPs for mean differ-
ences between the ddCD3 groups for donor age
(PP 5 0.83) and CD341 cell dose (PP 5 0.72), as
well as proportional differences between the ddCD3
groups for ATG dose (PP 5 0.80) and donor type
(PP 5 0.26).
NK cell reconstitution after SCT was evaluated to
examine its relationship with ddCD3 value. NK cell
counts were higher in the high ddCD3 group than in
the low ddCD3 group at 8 weeks (c21 5 4.1;
P 5 .044; PP 5 0.99). However, posttransplantation
NK cell recovery at 4 and 8 weeks did not influence
the ddCD3 count (c21 5 0.8; P 5 .37; PP 5 0.88).
We analyzed the effect of NK cell recovery on clinical
outcomes of interest, including GVHD (c21 5 0.4;
Biol Blood Marrow Transplant 18:794-804, 2012 801Donor-Derived CD3+ Cell Count in SCTP 5 .55), remission status (c21 5 2.4; P 5 .12), and
whole blood engraftment (c21 5 3.3; P 5 .07), as well
as on time-to-event measurements of mortality (P 5
.56), relapse (P5 .10), andGVHD(P5 .40), and unlike
with ddCD3 value, found no measurable independent
effect in our patient cohort.DISCUSSION
Cellular immune reconstitution after SCT
is known to be of prognostic relevance, particularly
with respect to relapse. Patients undergoing
T cell–depleted SCT have a higher rate of MC and
thus a higher rate of delayed immune reconstitution
with slower recovery of donor T cells. Neither chime-
rism analysis nor T cell subset recovery consistently
predicts the effect of withdrawing immunosuppression
in these patients. Patterns of T cell chimerism trends
generally fall into four broad categories: (1) early es-
tablishment of stable FC; (2) early MC evolving to
FC with withdrawal of immunosuppression; (3) stable
MC despite withdrawal of immunosuppression; and
(4) MC (or early FC) with late autologous reconstitu-
tion and graft loss [26-28]. Generally, patients with
MC have inferior outcomes; in particular, those with
high recipient chimerism in T cells are at a greater
risk for eventual graft loss when receiving a T cell–
depleted allograft. Clearly, early identification of the
chimerism pattern that a patient is likely to develop
will allow modification of therapy and reduce the risk
of relapse and graft loss in that patient.
To get a more accurate picture of the magnitude of
alloimmune reconstitution and its downstream effect,
we examined the impact of donor-derived T cell recov-
ery (ie, ddCD3 value) on posttransplantation out-
comes in patients conditioned with an ATG-based
preparative regimen. This parameter was calculated
from the simultaneously measured CD31 T cell chi-
merism and absolute CD31 cell count in circulation.
The earliest time point at which the ddCD3 value
could be determined in all of our patients was 8 weeks
after SCT. This was likely secondary to the effect of
ATG and the extended course of mycophenolate ther-
apy that our patients received for GVHD prophylaxis,
with the testing schedule an obvious determining
factor. Nevertheless, even at this relatively early time
point, ddCD3 had predictive value for clinical out-
comes developing later in the course of transplanta-
tion. This effect was particularly striking for donor
engraftment when the ROC curves for the effect of
ddCD3 value on common posttransplantation param-
eters were determined and when hematopoietic and T
cell chimerism were plotted over time for the high
ddCD3 and low ddCD3 groups at 8 weeks after
SCT. The absolute magnitude of donor T cell recov-
ery and its effect in our patients reflects the condition-ing regimen used and the underlying disease biology
and thus is unique to this patient population and
most likely subject to revision with a larger sample
size. This is particularly true because of the relatively
low ddCD3 cutoff value (110/mL) in our patients,
likely a manifestation of the TCD regimen. Thus,
the timing and magnitude of a prognostically impor-
tant ddCD3 value likely will differ based on the condi-
tioning regimen and particularly with different TCD
strategies.
Timing and magnitude aside, the most clinically
relevant aspect of the ddCD3 value is its association
with hematopoietic and T cell chimerism after with-
drawal of immunosuppression. Generally, mixed
T cell chimerism after reduced-intensity SCT is man-
aged by cessation of immunosuppression in T cell–re-
plete allografts; however, this may result in
progressive graft loss in T cell–depleted allografts, es-
pecially in patients with MC. That patients with
a higher ddCD3 have a more readily predictable tra-
jectory in both chimerism and T cell reconstitution
over time is intuitive and provides a discriminator
for decision making regarding DLI in recipients of
T cell–depleted reduced-intensity allografts. We did
not address whether this adds to the general value of
T cell chimerism measurement alone; however, it ap-
pears to be informative in our small dataset, particu-
larly when the downstream effects of T cell
engraftment (ie, relapse and GVHD) are examined.
Because this measure accounts for both quantitative
and qualitative donor T cell recovery posttransplanta-
tion through a simple calculation, the observed associ-
ation with downstream outcome is likely to be
confirmed in larger cohorts.
Similar findings have been reported in patients un-
dergoing transplantation after T cell–depleted alloge-
neic SCT and scheduled DLI. In a cohort of patients
with breast cancer, a relative preponderance of host-
derived T cells was observed at 28 and 100 days after
transplantation in patients with MC [29]. Conversely,
patients who developed grade II-IV GVHD despite
T cell depletion had a significantly higher number of
donor-derived T cells in circulation at day 100 [29].
These findings are consistent with our finding of
a higher rate of GVHD in patients with a higher
ddCD3 value at 8 weeks. Another study found that in
recipients of T cell–replete allografts conditioned
with fludarabine and 2 Gy TBI and with early discon-
tinuation of immunosuppression, a day 14 donor-
derived CD81 cell count .0.043*106/mL (.43/mL)
was strongly associated with grade II-IV acute
GVHD [30]. Similar to our cohort, no predictors for
donor-derived CD81 cell recovery were revealed by
an analysis of donor age and graft composition [30].
Taken together, these findings and our results suggest
that the magnitude of donor-derived T cell recovery
plays a critical role in alloimmune responses after SCT.
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relapse (and thus the need for DLI) in our patients,
two patients with a high ddCD3 value relapsed. Both
of these patients had heavily pretreated myeloma
with an adverse cytogenetic profile, suggesting the pri-
macy of disease biology in prognostic determination.
The adverse impact of disease status and cytogenetics
in patients undergoing reduced-intensity in vivo T
cell–depleted allografts is well known [31,32]. Thus,
ddCD3 values should be interpreted in light of
disease biology when used in decision making
regarding the need for DLI versus ongoing
immunosuppression in patients who have undergone
T cell–depleted reduced-intensity allogeneic SCT.
Our dataset is not large enough to establish
whether ddCD3 cell count can augment isolated T
cell chimerism and absolute T cell count in most pa-
tients undergoing SCT. Nonetheless, in selected pa-
tients with poor immune reconstitution, this more
precise metric has additional predictive value for
post-SCT outcomes beyond the factors that determine
it. In our estimation, ddCD3 cell count appears to be of
the greatest value in patients with low T lymphocyte
recovery or high levels of recipient chimerism. To bet-
ter understand this value, consider the general nature
of biological dose-response relationships, which often
tend to follow a sigmoid or logistic relationship with
threshold effects observed. Although this may not be
entirely true for T cell–mediated responses, which
are antigen specific, or binary, increasing donor-
derived T cell counts would increase the likelihood of
the presence of relevant recipient or tumor antigen-
specific T cell clones, thus the association of higher
ddCD3 counts withGVHDand freedom from relapse.
We speculate that our data best define outcomes of the
patients on the steep part of the aforementioned sig-
moid relationships between T cell reconstitution and
posttransplantation outcome likelihood. This is re-
flected by the ROC-AUC curves for GVHD, relapse,
and achievement of FC. Additional studies examining
the impact of ddCD3 in larger cohorts of patients are
needed before this value can be established as a qualita-
tive and quantitative measure to predict the onset and
magnitude of GVHD and graft-versus-tumor effects,
which are largely determined by minor histoincompa-
tibilities betweenHLA-identical donors and recipients
[33-35]. In addition, the likelihood of eventually
developing GVHD may be predicted more accurately
by assays such as T cell clonality.
The interaction between hematopoietic lineages
and T cells is likely important in determining the rate
and durability of T cell engraftment, as well as
donor-derived T cell recovery. In an investigation of
patterns in T cells and dendritic cells, MC in dendritic
cells withFC inTcells predicted the development of an
alloimmune response [36]. NK cell reconstitution after
allogeneic SCT has been studied as a predictor of post-transplantation outcomes and found to have variable
effects on such outcomes as graft rejection and relapse
[13,37,38]. Although we were not able to identify an
effect of posttransplantation NK cell reconstitution
on ddCD3 cell count recovery, patients with a high
ddCD3 cell count also had a higher NK cell count at
the 8-week mark, suggesting interactions among fac-
tors that determine cellular immune reconstitution.
None of the graft and patient characteristics that we
studied, including CD31 cell dose infused and ATG
dose used in conditioning,was predictive of cellular im-
mune recovery. However, such parameters as ATG
level at the time of transplantation, tacrolimus andmy-
cophenolate levels after transplantation, andminor his-
tocompatibility differences are not accounted for in our
analysis and may well have a deterministic effect on
ddCD3 cell recovery and subsequent outcomes.
Thus, it is reasonable to conclude that clinicians caring
for SCT recipients should closely monitor cellular im-
mune reconstitution after transplantation and, depend-
ing on disease biology, intervene with suchmeasures as
DLI if this process is delayed.
Our findings must be considered only preliminary,
keeping in mind the small sample size of our cohort
and the heterogeneity of disorders for which the
SCTs were performed. Thus, to increase the confi-
dence in the validity of our findings, we evaluated
Bayes methods along with our proposed classical
methods, because they account for small sample sizes
and yield interpretable inference on the parameters
of interest, rate or mean differences, that is often sim-
ilar to inference from frequentist methods [39]. In
analyses such as ours, a particular concern is that a sub-
stantial sample size may be required to deliver ade-
quate statistical power and yield appropriate
asymptotic behavior of the statistics being used [25].
However, the posterior probabilities obtained using
Bayes methods are valid even for small sample sizes,
given that those probabilities are conditioned on the
observed data and, by necessity, on the sample size.
Thus, a posterior probability reflects the data at hand
and requires more statistical evidence to produce
a high probability with smaller sample sizes than
with larger sample sizes.
In conclusion, here we report the effect of donor T
cell reconstitution, easily calculated from routinely
measured posttransplantation variables, on clinical
outcomes, particularly the stability of engraftment
and disease relapse. The ddCD3 cell count may aid in
the decision making regarding withdrawal of immuno-
suppression and timingofDLI in recipients of in vivoT
cell–depleted allografts. The optimal ddCD3 cutoff
value needs to be refined by examining this parameter
in larger patient cohorts with comparable disease biol-
ogy over a longer period of time and with a wider range
of conditioning regimens before this parameter can be
widely applied in the clinical setting.
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